Canine demodicosis (demodectic mange) diagnostic and treatment guide. Localized vs generalized disease, skin scrape diagnostics, isoxazoline treatment, and openFDA lack-of-efficacy analysis.

Canine demodicosis, commonly known as demodectic mange, is an inflammatory parasitic skin disease caused by the overgrowth of microscopic, cigar-shaped mites of the genus Demodex. Unlike other mange mites, Demodex mites are normal inhabitants of canine skin, living commensally inside hair follicles and sebaceous glands.

Because these mites are part of the normal microfauna, clinical demodicosis is fundamentally an immunological disease rather than a simple infestation. When a dog's local or systemic immune response fails to regulate the mite population, the parasites multiply rapidly, leading to folliculitis, alopecia, secondary bacterial infections, and severe pruritus. Managing demodicosis requires distinguishing between localized and generalized forms, identifying the age of onset, and implementing a diagnostic-led treatment plan. This guide provides a clinical analysis of demodicosis staging, deep skin scraping SOPs, the modern treatment ladder, and real-world treatment-efficacy data from the openFDA adverse-event database.

Quick answer

Canine demodicosis is a non-contagious skin disease caused by the proliferation of Demodex canis (or less commonly, Demodex injai or Demodex cornei) due to immune system dysfunction. It is diagnosed by confirming the presence of mites, eggs, or immature stages on deep skin scrapings or hair pluck trichography. It is clinically divided into localized (fewer than 5 small, well-demarcated hairless patches) and generalized (widespread lesions, pododemodicosis, or secondary infection).

Furthermore, the disease is classified by age of onset: juvenile-onset (typically appearing before 1.5 years of age, often secondary to transient developmental immune weakness) and adult-onset (occurring in dogs older than 1.5 to 2 years, which represents a diagnostic red flag indicating severe underlying immunosuppressive disease like Cushing's, hypothyroidism, cancer, or drug-induced immunosuppression).

First-line treatment has transitioned away from toxic amitraz dips and daily oral ivermectin toward the oral isoxazoline class of parasiticides—including fluralaner (Bravecto), sarolaner (Simparica), afoxolaner (NexGard), and lotilaner (Credelio). Efficacy is monitored with monthly deep skin scrapings, and treatment must be continued until obtaining two consecutive negative scrapings spaced 2 to 4 weeks apart.

Real-world pharmacovigilance data from the openFDA database (1,247 unique mite-related reports, including 1,169 canine cases) reveals a substantial lack of efficacy signal, with 330 reports of ectoparasitic demodex failure and 110 reports of ineffective demodex treatment, highlighting the emergence of treatment resistance and the critical impact of unresolved underlying systemic disease.

What is demodectic mange, and how is it different from sarcoptic mange?

Many pet owners and veterinary staff use the terms "mange" and "scabies" interchangeably. However, demodectic mange and sarcoptic mange are biological opposites in terms of transmission, zoonotic risk, and pathophysiology.

Mite Biology: Demodex canis

commensal Nature: Demodex canis is a normal resident of healthy canine skin. The mites are transmitted from the mother to the nursing puppies during the first few days of life through direct skin-to-skin contact. They cannot survive off the host.
Location: The mites reside deep within the hair follicles and sebaceous glands, feeding on sebum, cellular debris, and follicular epithelial cells.
Transmission Risk: Because the mites are already present on almost all healthy dogs, demodicosis is not considered contagious. A healthy dog can interact with a dog suffering from active demodectic mange without contracting the clinical disease, as their immune system will prevent the mites from multiplying.

Mite Biology: Sarcoptes scabiei (Sarcoptic Mange / Canine Scabies)

Obligate Parasite: Sarcoptes scabiei var. canis is a highly contagious, acquired parasite. It is not part of the normal skin microfauna.
Location: The female mites burrow tunnels directly into the stratum corneum of the epidermis to lay their eggs, causing a hypersensitivity reaction.
Transmission Risk: Sarcoptic mange is highly contagious through direct contact or contaminated bedding. Furthermore, it is zoonotic, meaning it can easily transmit to humans, causing a transient, intensely itchy papular eruption (typically on the arms, chest, and abdomen) that self-limits once the dog is treated.

Comparative Clinical Presentation

Feature	Demodectic Mange (Demodex canis)	Sarcoptic Mange (Sarcoptes scabiei)
Contagious to Other Dogs?	No (requires host immune dysfunction)	Yes (highly contagious)
Contagious to Humans?	No (human demodex species are distinct)	Yes (zoonotic; causes transient pruritus)
Primary Lesion Sites	Face, periocular skin, forelimbs (localized); widespread (generalized)	Pinnae (ear margins), elbows, hocks, ventrum
Pruritus (Itching) Level	None to Mild (unless secondary bacterial infection is present)	Intense, Unremitting (often out of proportion to visible lesions)
Pinnal-Pedal Reflex	Typically negative	Positive in > 80-90% of cases (rubbing the ear margin causes hind-leg scratching)

Localized vs. Generalized, and Juvenile vs. Adult-Onset

Correctly classifying demodicosis is the most important step in formulating a prognosis and determining whether to initiate therapy or pursue a diagnostic workup.

                           [CANINE DEMODICOSIS CLASSIFICATION]
                                           |
                   +-----------------------+-----------------------+
                   |                                               |
                   v                                               v
         [Localized Form]                                  [Generalized Form]
         - < 5 focal lesions                               - >= 5 lesions or large patches
         - Self-limiting (90% resolve)                     - Chronic / Widespread
         - Do not treat (monitor)                          - Requires active therapy
                   |                                               |
                   +-----------------------+-----------------------+
                                           |
                   +-----------------------+-----------------------+
                   |                                               |
                   v                                               v
         [Juvenile-Onset (< 1.5 yrs)]                     [Adult-Onset (> 1.5-2 yrs)]
         - Developmental immune lag                        - IMMUNOLOGICAL RED FLAG
         - Excellent prognosis                             - Search for Cushing's, thyroid,
                                                             neoplasia, or drug immunosuppression

Localized vs. Generalized Disease

The international consensus guidelines (Mueller et al., 2020) define these categories as follows:

Localized Demodicosis:
- Presentation: Fewer than five small, well-demarcated, focal patches of alopecia, erythema, and mild scaling. These lesions are most common on the face (periocular area, commissures of the mouth) and forelimbs.
- Clinical Approach: Approximately 90% of localized juvenile cases resolve spontaneously without medical treatment within 6 to 8 weeks, as the puppy's immune system matures. Active treatment with parasiticides is contraindicated for localized cases because it can mask the progression of the disease to the generalized form. The clinical recommendation is to monitor the lesions and support the skin barrier.
Generalized Demodicosis:
- Presentation: Five or more focal lesions, large coalescing patches of hair loss and inflamed skin, or involvement of entire body regions. This form often includes pododemodicosis (involvement of the paws, characterized by severe swelling, pain, deep pyoderma, and draining tracts).
- Clinical Approach: Requires immediate, active parasiticide therapy and secondary antibiotic or antifungal management.

Juvenile-Onset vs. Adult-Onset Disease

The age at which generalized demodicosis first develops determines the diagnostic workflow:

Juvenile-Onset (Under 1.5 Years):
- Etiology: Associated with transient, genetically preprogrammed immune system lags or hereditary T-cell dysfunction. Certain breeds (such as the English Bulldog, French Bulldog, Staffordshire Bull Terrier, Pit Bull, Pug, and Boston Terrier) are highly predisposed.
- Prognosis: Excellent with modern therapies. Once cleared, the dog's immune system typically prevents recurrence.
Adult-Onset (Over 1.5 to 2 Years):
- Etiology: Adult-onset generalized demodicosis is a major immunologic warning. Because these dogs had healthy adult immune systems that previously regulated the mite population, a sudden overgrowth indicates that a severe, systemic disease has compromised their immune response.
- Workup Mandate: The veterinarian must search for the underlying cause. Common triggers include:
  - Hyperadrenocorticism (Cushing's Disease): Excess cortisol suppresses cell-mediated immunity.
  - Hypothyroidism: Thyroid hormone deficiencies impair skin cell metabolism and immune defense.
  - Neoplasia: Lymphoma, carcinoma, or other systemic cancers.
  - Iatrogenic Immunosuppression: Chronic administration of corticosteroids (like prednisone or Apoquel) or chemotherapeutic drugs.

Differentiating Demodicosis from Other Common Canine Skin Diseases

Because generalized demodicosis presents with alopecia, erythema, scaling, and secondary pyoderma, it can be easily misdiagnosed as other common dermatological conditions. Veterinary teams must perform targeted differentials to rule out:

Bacterial Folliculitis: A superficial bacterial infection of the hair follicles, typically caused by Staphylococcus pseudintermedius. It produces circular patches of hair loss with crusts and collarettes that look identical to localized demodicosis. A deep skin scraping and skin cytology help differentiate the two.
Dermatophytosis (Ringworm): A fungal infection of the hair shaft and stratum corneum, most commonly caused by Microsporum canis. Like demodicosis, it causes focal, expanding patches of hair loss and scaling. It is ruled in or out using a Wood's lamp, trichography, or a dermatophyte test medium (DTM) culture.
Sarcoptic Mange: While sarcoptic mange is contagious and intensely itchy, it can look similar in its early stages. A positive pinnal-pedal reflex strongly suggests sarcoptic mange, and a superficial skin scraping (rather than a deep scraping) is used to find Sarcoptes mites, which are broader and rounder than the cigar-shaped Demodex mites.
Canine Atopic Dermatitis: Allergic skin disease causes itching and redness, but typically lacks the primary, well-demarcated alopecia of demodicosis. However, allergic dogs are frequently prescribed immunosuppressive doses of steroids or Apoquel, which can trigger secondary adult-onset demodicosis as a complication.

How is demodicosis diagnosed?

Clinical signs alone are insufficient to diagnose demodicosis, as other conditions (like dermatophytosis, bacterial folliculitis, or allergic skin disease) can present with similar hair loss and scaling. Clinicians must confirm the presence of mites using point-of-care microscopy.

Step-by-Step SOP: Deep Skin Scraping

Deep skin scraping is the gold standard diagnostic method for detecting follicular mites:

Select the Site: Choose active, erythematous, scaling lesions that have not been scrubbed or cleaned.
Prepare the Slide: Place a drop of mineral oil directly onto a clean glass slide and dip the scraping instrument (a dull #10 scalpel blade or a small spatula) into the oil to help capture the scraped debris.
Extrude the Mites: Gently squeeze the skin between your thumb and forefinger at the scrape site. Squeezing compresses the hair follicles, forcing the mites out of the deep follicular canals and toward the skin surface.
Scrape to Bleed: Hold the dull blade at a 45-degree angle to the skin. Scrape in the direction of hair growth until capillary bleeding is observed. Capillary bleeding is the essential endpoint; because Demodex canis lives deep in the follicles, scraping only superficial epidermis will yield false negative results.
Examine the Sample: Transfer the scraped material to the glass slide. Apply a coverslip and lower the microscope condenser to increase contrast. Systematically scan the slide under 4× and 10× magnification.

                           [DEEP SKIN SCRAPING SOP]
                                      |
                                      v
                        [Select Active Red/Scaly Site]
                                      |
                                      v
                        [Apply Mineral Oil to Skin/Blade]
                                      |
                                      v
                        [Squeeze Skin (Extrude Mites)]
                                      |
                                      v
                    [Scrape Until CAPILLARY BLEEDING Appears]
                                      |
                                      v
                       [Transfer to Slide & Scan under 4x/10x]

Hair Pluck (Trichography)

For sensitive areas where a scraping instrument is dangerous—such as close to the eyelid margins (periocular skin) or between the toes (interdigital spaces)—hair plucking is an excellent alternative:

Procedure: Use hemostats to grasp 10 to 20 hairs close to the skin surface and pull them out in the direction of growth.
Mounting: Place the hair bulbs in mineral oil on a slide, apply a coverslip, and examine the hair roots. Mites will be visible clinging to the base of the hair shaft inside the root sheath.

Microscopic Interpretation

The veterinarian must record the counts of:

Adult Mites: Cigar-shaped, eight-legged, long-bodied structures.
Immature Stages: Nymphs (eight legs, shorter body), larvae (six legs), and eggs (lemon-shaped or rhomboid).

Finding immature stages or eggs indicates that the mite population is actively reproducing and suggests that the infection is active and likely to progress.

What is the treatment ladder for canine demodicosis?

Once generalized demodicosis is confirmed, the veterinary team must implement a structured treatment protocol. The treatment landscape has been revolutionized in recent years by the introduction of the isoxazoline class of drugs.

1. The Isoxazoline Class (First-Line)

Although originally labeled for flea and tick prevention, the isoxazoline class has become the international consensus first-line treatment for canine demodicosis due to its high efficacy and safety profile:

Sarolaner (Simparica): Administered orally once monthly at a dose of 2.0 to 4.0 mg/kg.
Fluralaner (Bravecto): Administered orally once every 8 to 12 weeks at a dose of 25.0 to 56.0 mg/kg. To review this drug, see our guide to Bravecto (fluralaner) for dogs.
Afoxolaner (NexGard): Administered orally once monthly at a dose of 2.5 to 5.0 mg/kg.
Lotilaner (Credelio): Administered orally once monthly at a dose of 20.0 to 40.0 mg/kg.

Mechanism of Action: Isoxazolines block ligand-gated chloride channels, specifically targeting gamma-aminobutyric acid (GABA) and glutamate receptors in the mite's central nervous system, leading to hyperexcitation and death. Because mammalian GABA receptors differ structurally, these drugs exhibit a wide safety margin in dogs. For details on class-wide warnings, consult our guide to isoxazoline safety for dogs and cats.

2. Daily Macrocyclic Lactones (Second-Line)

Before the introduction of isoxazolines, daily administration of macrocyclic lactones was the standard therapy. This pathway is now reserved for cases where isoxazolines are unavailable or contraindicated:

Ivermectin: Administered orally once daily at a dose of 0.3 to 0.6 mg/kg/day.
MDR1 (ABCB1) Gene Mutation Warning: Ivermectin must never be administered to Collies, Shetland Sheepdogs, Australian Shepherds, Old English Sheepdogs, or other herding breeds without prior genetic screening. These breeds often carry a mutation in the ABCB1 (formerly MDR1) gene, which encodes P-glycoprotein—a pump responsible for keeping toxins from crossing the blood-brain barrier. In dogs with the mutation, ivermectin accumulates in the central nervous system, causing severe neurotoxicity characterized by pupil dilation (mydriasis), depression, tremors, ataxia, recumbency, coma, and death.

3. Amitraz Dips (Historical / Third-Line)

Amitraz (Mitaban) was the first FDA-approved treatment for generalized demodicosis:

Protocol: Diluted dip applied to the entire body once every 14 days.
Side Effects: Amitraz is a monoamine oxidase inhibitor (MAOI) and alpha-2 adrenergic agonist. It causes severe sedation, hypothermia, bradycardia, and transient hyperglycemia. Application must be performed in a well-ventilated clinic setting using protective gear. Because of these safety hazards and the high success rate of oral isoxazolines, amitraz is rarely used in modern veterinary practice.

The Challenge of Pododemodicosis and Otodemodicosis

Two specific regional presentations of demodicosis represent significant therapeutic challenges:

Pododemodicosis (Mange of the Feet): Demodex infestation of the paws is notoriously resistant to therapy. The friction of walking, deep follicular structure of paw skin, and frequent secondary deep bacterial pyoderma and furunculosis make clearance slow. paw skin becomes swollen, fibrotic, painful, and prone to draining tracts. Even when the body skin is cleared, mites can persist in the paws. Treatment with oral isoxazolines must be maintained consistently, often combined with daily chlorhexidine foot baths and long-term systemic antibiotics based on culture and sensitivity.
Otodemodicosis (Ear Mange): Demodex can infest the external ear canals, causing ceruminous otitis externa. Diagnosis is made by cerumen cytology, which reveals the mites. Treating otodemodicosis requires systemic isoxazolines and topical ear cleaning; local corticosteroid ear drops must be strictly avoided, as they will promote mite reproduction. For ear infection context, see our guide to otitis externa in dogs.

Why is adult-onset generalized demodicosis a diagnostic red flag?

When generalized demodicosis is diagnosed in an adult dog (older than 1.5 to 2 years), treating the mites is only half the battle. The mites are proliferating because the dog's immune system has been compromised. If the underlying cause is not identified and managed, the demodicosis is highly likely to recur or fail to respond to treatment.

The diagnostic workup for adult-onset demodicosis must include:

Detailed Drug History: Review all medications administered over the past 6 months. In particular, look for long-term corticosteroid administration (oral prednisone, topical ear drops containing dexamethasone, or allergy injections like Depo-Medrol) or immunomodulatory therapies like Apoquel (oclacitinib). Long-term immunosuppression suppresses cell-mediated immunity, allowing normal commensal mites to multiply.
Endocrine Screening:
- Low-Dose Dexamethasone Suppression Test (LDDST): To screen for hyperadrenocorticism (Cushing's disease). For details on screening protocols, see our guide to Cushing's disease testing and trilostane monitoring.
- Thyroid Panel (Total T4, Free T4, TSH): To rule out hypothyroidism, which impairs normal skin turnover and cellular immunity.
Oncology Search: A complete physical exam including palpation of all peripheral lymph nodes, thoracic radiographs, and abdominal ultrasound to screen for occult neoplasia (like lymphoma or internal carcinomas).

What does the openFDA adverse-event record show?

To understand how demodicosis treatments perform in the field, we analyzed the US FDA Center for Veterinary Medicine’s animal drug adverse-event reports through the openFDA animal and veterinary adverse-event API. We filtered for reports containing reaction terms related to mites (Demodex, Sarcoptes, mange, scabies).

The database search yielded 1,247 unique adverse-event reports involving these parasiticide-resistant or mite-related terms.

Species and Demographic Breakdown

The data confirms that mite-related clinical concerns are overwhelmingly canine:

Dog Reports: 1,169 (93.7%)
Cat Reports: 59 (4.7%)
Other Species (Cattle, Pig, Goat, etc.): 19 (1.6%)

Top Mite-Specific and Efficacy Reactions

Analyzing the specific reaction terms in the database reveals a significant number of "lack of efficacy" reports, which highlights that treatment failures are a documented clinical reality.

VeDDRA Reaction Term	Report Count	Clinical Significance & Interpretation
Lack of efficacy (ectoparasite) - Sarcoptes	486	Indicates failure to clear Sarcoptes mites. Often associated with incorrect dosing frequency or incomplete treatment duration.
Lack of efficacy (ectoparasite) - Demodex	330	Represents confirmed treatment failure for demodectic mange. Points to emerging resistance or unresolved underlying immunosuppression.
Demodicosis	230	Indicates active, clinical demodex infection reported as an adverse event.
INEFFECTIVE, DEMODEX MITES	110	Additional reporting code confirming treatment failure for Demodex.
INEFFECTIVE, SARCOPTES MITES	96	Additional reporting code confirming treatment failure for Sarcoptes.
Lack of efficacy - NOS	59	General lack of efficacy code; represents cases where the specific parasite was not detailed.

Analyzing the Efficacy Signal

Combining the demodex-specific terms yields 440 total reported treatment failures ("Lack of efficacy - Demodex" + "INEFFECTIVE, DEMODEX MITES").

When interpreting these numbers, clinicians must evaluate several potential causes for a reported lack of efficacy:

Unmanaged Underlying Disease: In adult-onset cases, the parasiticide may kill the mites, but if the dog's Cushing's disease or steroid therapy is not addressed, the mite population will continue to multiply. The "treatment failure" is often a failure to address the underlying immunosuppressive trigger.
Incomplete Treatment Course: Owners often stop administering the parasiticide once the dog's hair begins to grow back. However, clinical recovery occurs long before parasitologic clearance. Stopping treatment before obtaining two consecutive negative skin scrapings allows the remaining mites to multiply, leading to recurrence.
Emerging Resistance: While the isoxazolines remain highly effective, these 440 reports support the emerging clinical discussion regarding potential mite resistance to certain macrocyclic lactones and first-generation isoxazolines.

Demodicosis in Dogs FAQs

Is demodectic mange in dogs contagious to other dogs or to people?

No. Demodex canis is a normal resident of healthy canine skin and is not considered contagious. The mites are transmitted from mother to pup during nursing but do not cause clinical disease unless the dog's immune system fails to regulate them. Furthermore, Demodex mites are species-specific; canine Demodex cannot survive or reproduce on human skin or on cats.

What is the best treatment for demodex in dogs - ivermectin, Bravecto, or NexGard?

The oral isoxazoline class—which includes Bravecto (fluralaner), NexGard (afoxolaner), Simparica (sarolaner), and Credelio (lotilaner)—is the current gold standard first-line treatment. Isoxazolines have largely replaced daily oral ivermectin because they are highly effective, have a wide safety margin, and do not carry the same risk of causing severe neurotoxicity in dogs with the ABCB1 (MDR1) gene mutation.

My adult dog suddenly got demodex - what underlying cause should the veterinarian look for?

Adult-onset generalized demodicosis is a clinical warning that the dog’s immune system has been compromised. Your veterinarian should review the dog's medication history for immunosuppressive drugs (such as corticosteroids or Apoquel) and perform endocrine tests to screen for hyperadrenocorticism (Cushing's disease) and hypothyroidism. A thorough search for occult neoplasia (like lymphoma) is also indicated.

Why can't some Collies and herding breeds take ivermectin for demodex?

Many Collies, Shetland Sheepdogs, Australian Shepherds, and related herding breeds carry a mutation in the ABCB1 (formerly MDR1) gene. This mutation causes a defect in P-glycoprotein, a transport pump that keeps certain drugs from crossing the blood-brain barrier. In affected dogs, daily high-dose ivermectin accumulates in the brain, causing life-threatening neurotoxicity (tremors, blindness, coma, and death).

Sources

Mueller, R. S., Rosenkrantz, W., Bensignor, E., et al. (2020). Diagnosis and treatment of demodicosis in dogs and cats: Clinical consensus guidelines of the World Association for Veterinary Dermatology. Veterinary Dermatology, 31(1), 5-27. https://wavd.org/wp-content/uploads/diagnosis-and-treatment-of-demodicosis-in-dogs-and-cats-mueller-et-al-2020-veterinary-dermatology.pdf
Merck Veterinary Manual. Mange in Dogs and Cats. https://www.merckvetmanual.com/integumentary-system/mange/mange-in-dogs-and-cats
Companion Animal Parasite Council (CAPC). CAPC Parasite Guidelines: Demodex. https://capcvet.org/guidelines/
Mueller, R. S. (2019). An update on the treatment of canine demodicosis. Today's Veterinary Practice, Dermatology Details. https://todaysveterinarypractice.com/dermatology/dermatology-detailsupdates-management-canine-demodicosis/
Djurić, M., et al. (2019). Efficacy and safety of isoxazolines for the treatment of generalized demodicosis in dogs: A critically appraised topic. BMC Veterinary Research, 15, 218. https://pmc.ncbi.nlm.nih.gov/articles/PMC6323682/
U.S. Food and Drug Administration (FDA). Center for Veterinary Medicine animal drug adverse-event reports, accessed through the openFDA Animal and Veterinary Adverse Event API. https://open.fda.gov/apis/animalandveterinary/event/

Vet Med Guide

Demodicosis in Dogs: Diagnosis, Treatment, and the openFDA Record